'We have to rise over our divisions.' 'Divisions within us allow unscrupulous politicians to divert attention from issues like corruption and governance.'
India has airlifted more than 6 million COVID-19 doses to nine countries in Phase-I under its initiative termed "Vaccine Maitri".
The growth prospects are particularly high for Indian companies in the speciality and complex generic drugs segment in the US, the report said.
Regulators tighten net on safety grounds.
.jpg)
After a high-level meeting held on Friday chaired by Prime Minister Manmohan Singh, it has been decided that the Commerce and Industry would soon start a consultation process to address 'dangers inherent' in the current model of FDI in brownfield pharma units.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
In his press conference on Wednesday, Trump targeted drug-makers and vowed to bring back production in the US.
Zydus Pharmaceuticals Inc, the US arm of Zydus Cadila has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market generic products in the US.
Drug firm Strides Acrolab on Tuesday said it is in a position to supply Oseltamivir Capsules, the only available medicine against Influenza A HINI virus (Swine Flu), to meet the demand both from domestic and overseas market.
Calling the FIR against the army as 'unfortunate', Lt Gen Anbu said that there should have been generic FIR in the matter.
The Indian Medical Association and the Mumbai Association of Medical Consultant have written a letter to Narendra Modi expressing disappointment over his statement during the Bharat ki Baat Sabke saath event in London.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally.
The government plans to rationalise trade margins for many other medical devices, besides stents and knee implants.
Indian firm to soon launch copycat of anti-breast-cancer drug.
Last year, the USFDA had banned 30 generic drugs produced at Ranbaxy's plants at Poanta Sahib.
China is on the lookout for investment pastures where its money is welcome, safe and earns a decent return. India also needs vast investment - about $1 trillion over the next 10-15 years - in infrastructure, green energy, transportation and heavy industry, says Ravi Bhoothalingam.
Sayre Therapeutics aims for a spot among top 5 players in oncology.
Domestic firms Aurobindo Pharma, Glenmark Pharmaceuticals and Natco Pharma have received US health regulator's approval to market their generic Rizatriptan Benzoate orally disintegrating tablets used for treating migraine in the American market.
Aurobindo pharma, cipla, orchid chemicals are the prominent takeover targets.
Drug maker Marksans Pharma on Thursday said it has acquired UK-based generic pharmaceutical company Relonchem for an undisclosed amount.
We asked readers to give their reasons as to why Katappa killed Baahubali in the hugely-awaited film Baahubali: The Conclusion, and we got some amazing answers.
The US government is threatening to obstruct low-income countries from accessing generic HIV/AIDS drugs approved by the World Health Organization, a human rights group charged on Friday.
While Watson is a near comparable to Ranbaxy in terms of the generics business in the US, on margins and capital efficiency front, Ranbaxy is way ahead of Watson.
At any time, there is a need to operationally deploy two aircraft carriers in the vast Indian Ocean, asserts Vice Admiral Premvir Das (retd).
Indian pharma firms under European drug regulator's scanner.
One reason Japan is betting highly on Indian pharma is that these companies have strong cash flows, low leverage and high debt capacity for medium to large sized acquisitions.
A widening probe by US authorities involving top drug companies following complaints of price fixing of generics was a point of worry for the participants, said analysts.
Indian wines are getting better all the time, says Alok Chandra.
India's pharma companies are moving beyond generics to set their sights on the research and development of new drugs, but the risks are many
Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With More drugmakers in line to launch the drug soon, the prices may see a further erosion.
'The reality of this virus is that as long as it is circulating, it can mutate into new variants and by the time you realise that this is a new virus, which is more dangerous, and more transmissible, it is too late.'
The spread of COVID-19 and the accompanying mayhem caused the S&P BSE Sensex to drop over 38.5 per cent from its all-time high of 42,273.9 to a low of 25,981.2 on March 23. Those in the astrology and even numerology segments received more calls than before during the time.
India's top drug maker Ranbaxy Laboratories said on Tuesday its first-quarter net profit nearly tripled on booming exports of generic drugs to the United States.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
After a detailed scrutiny, fair trade watchdog CCI has suggested Sun Pharma and Ranbaxy to make certain changes in their proposed $4 billion merger deal, including possible divestment of some brands, to address anti-competitive concerns.
.jpg)
Global pharmaceutical firms have had a series of patent disputes with Indian makers of generic drugs and several recent Indian rulings have gone against the international giants.
The Canadian health and drug regulator Health Canada has asked Ranbaxy Pharmaceuticals Canada (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) to withdraw its generic, 25 microgram per hour strength, fentanyl pain-relief patches from the Canadian market due to safety concerns.
Indian drugmaker Dr Reddy's Laboratories hopes to launch two-to-three generic products in the United States this year in a bid to increase its share of a lucrative market, its chief executive said.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances